Bioconversion of plant biomass hydrolysate into bioplastic (polyhydroxyalkanoates) using Ralstonia eutropha 5119

Bhatia, Shashi Kant; Gurav, Ranjit; Choi, Taekjib; Jung, Hye-Rim; Yang, Seun-Ah; Moon, Yu-Mi; Song, Hun-Suk; Jeon, Ji-Hong; Choi, Kwon‐Young; Yang, Yung‐Hun

doi:10.1016/j.biortech.2018.09.122

Cited by 156 publications

(32 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The advantage of combination therapies is the reduction in the antibiotic concentration used, as multiple activities can better attenuate or evade the antibiotic-resistance mechanisms of pathogenic bacteria. Response surface methodology analysis using the Box–Behnken design was introduced to set up the optimal concentration of three antibacterial agents to effectively eliminate MRSA [ 21 , 22 , 23 ]. Using concentrations higher than the MIC of each compound is meaningless; thus, the MIC 50 of each agent was selected for the Box–Behnken design using Minitab 18 software to analyze the interaction and examine the desired response.…”

Section: Resultsmentioning

confidence: 99%

Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus

et al. 2020

Self Cite

View full text Add to dashboard Cite

The overuse of antibiotics has led to the emergence of multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). MRSA is difficult to kill with a single antibiotic because it has evolved to be resistant to various antibiotics by increasing the PBP2a (mecA) expression level, building up biofilm, introducing SCCmec for multidrug resistance, and changing its membrane properties. Therefore, to overcome antibiotic resistance and decrease possible genetic mutations that can lead to the acquisition of higher antibiotic resistance, drug combination therapy was applied based on previous results indicating that MRSA shows increased susceptibility to free fatty acids and surfactants. The optimal ratio of three components and the synergistic effects of possible combinations were investigated. The combinations were directly applied to clinically isolated strains, and the combination containing 15 μg/mL of oxacillin was able to control SCCmec type III and IV isolates having an oxacillin minimum inhibitory concentration (MIC) up to 1024 μg/mL; moreover, the combination with a slightly increased oxacillin concentration was able to kill SCCmec type II. Phospholipid analysis revealed that clinical strains with higher resistance contained a high portion of 12-methyltetradecanoic acid (anteiso-C15:0) and 14-methylhexadecanoic acid (anteiso-C17:0), although individual strains showed different patterns. In summary, we showed that combinatorial therapy with a low concentration of oxacillin controlled different laboratory and highly diversified clinical MRSA strains.

show abstract

Section: Resultsmentioning

confidence: 99%

Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…PHAs can be obtained from over 155 monomer subunits through fermentation by some bacteria from different renewable carbon sources that are accumulated as intracellular storage granules (8). For instance, Bhatia et al (9) obtained high biomass (Y x/s , 0.31 g/g) and PHA (Y p/s , 0.14 g/g) yields using Ralstonia eutropha 5,119 bacteria and Miscanthus biomass hydrolysate (MBH) as carbon source. In another research work, Bhatia et al (10) obtained a high PHB production (1.24 g/L) with 2% (w/v) starch as carbon source, using a Escherichia coli (E. coli) strain produced using different plasmids containing the amylase gene of Panibacillus sp.…”

Section: Introductionmentioning

confidence: 99%

Development of Electrospun Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Monolayers Containing Eugenol and Their Application in Multilayer Antimicrobial Food Packaging

et al. 2020

View full text Add to dashboard Cite

In this research, different contents of eugenol in the 2.5-25 wt.% range were first incorporated into ultrathin fibers of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) by electrospinning and then subjected to annealing to obtain antimicrobial monolayers. The most optimal concentration of eugenol in the PHBV monolayer was 15 wt.% since it showed high electrospinnability and thermal stability and also yielded the highest bacterial reduction against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). This eugenol-containing monolayer was then selected to be applied as an interlayer between a structural layer made of a cast-extruded poly(3-hydroxybutyrate) (PHB) sheet and a commercial PHBV film as the food contact layer. The whole system was, thereafter, annealed at 160 • C for 10 s to develop a novel multilayer active packaging material. The resultant multilayer showed high hydrophobicity, strong adhesion and mechanical resistance, and improved barrier properties against water vapor and limonene vapors. The antimicrobial activity of the multilayer structure was also evaluated in both open and closed systems for up to 15 days, showing significant reductions (R ≥ 1 and < 3) for the two strains of food-borne bacteria. Higher inhibition values were particularly attained against S. aureus due to the higher activity of eugenol against the cell membrane of Gram positive (G+) bacteria. The multilayer also provided the highest antimicrobial activity for the closed system, which better resembles the actual packaging and it was related to the headspace accumulation of the volatile compounds. Hence, the here-developed multilayer fully based on polyhydroxyalkanoates (PHAs) shows a great deal of potential for antimicrobial packaging applications using biodegradable materials to increase both quality and safety of food products.

show abstract

“…Thus, the use of waste materials as carbon sources for microbial-derived PHA production has been proposed in order to simultaneously reduce both PHA production and waste disposable costs (Choi and Lee, 1999; Kim, 2000; Koller et al, 2017; Nielsen et al, 2017). Several waste sources have been used to produce PHAs with relative success (Marshall et al, 2013; Nikodinovic-Runic et al, 2013; Anjum et al, 2016; Koller et al, 2017), including domestic wastewater (Carucci et al, 2001); food waste (Rhu et al, 2003); molasses (Albuquerque et al, 2007; Carvalho et al, 2014); olive oil mill effluents (Dionisi et al, 2005); palm oil mill effluents (Din et al, 2012); tomato cannery water (Liu et al, 2008); lignocellulosic biomass (Bhatia et al, 2019); coffee waste (Bhatia et al, 2018); starch (Bhatia et al, 2015); biodiesel industry waste (Kumar et al, 2014a; Sathiyanarayanan et al, 2017); used cooking oil (Ciesielski et al, 2015; Kourmentza et al, 2017); pea-shells (Patel et al, 2012; Kumar et al, 2014b); paper mill wastewater (Jiang et al, 2012); bio-oil from the fast-pyrolysis of chicken beds (Moita and Lemos, 2012); and cheese whey (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Prospects for the Use of Whey for Polyhydroxyalkanoate (PHA) Production

et al. 2019

View full text Add to dashboard Cite

Plastic production and accumulation have devastating environmental effects, and consequently, the world is in need of environmentally friendly plastic substitutes. In this context, polyhydroxyalkanoates (PHAs) appear to be true alternatives to common plastics because they are biodegradable and biocompatible and can be biologically produced. Despite having comparable characteristics to common plastics, extensive PHA use is still hampered by its high production cost. PHAs are bacterial produced, and one of the major costs associated with their production derives from the carbon source used for bacterial fermentation. Thus, several industrial waste streams have been studied as candidate carbon sources for bacterial PHA production, including whey, an environmental contaminant by-product from the dairy industry. The use of whey for PHA production could transform PHA production into a less costly and more environmentally friendly process. However, the efficient use of whey as a carbon source for PHA production is still hindered by numerous issues, including whey pre-treatments and PHA producing strain choice. In this review, current knowledge on using whey for PHA production were summarized and new ways to overcome the challenges associated with this production process were proposed.

show abstract

Bioconversion of plant biomass hydrolysate into bioplastic (polyhydroxyalkanoates) using Ralstonia eutropha 5119

Cited by 156 publications

References 41 publications

Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus

Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus

Development of Electrospun Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Monolayers Containing Eugenol and Their Application in Multilayer Antimicrobial Food Packaging

Prospects for the Use of Whey for Polyhydroxyalkanoate (PHA) Production

Contact Info

Product

Resources

About